Brief: Bright Minds Biosciences Says Financial Runway Extending Into 2026
12/09/2024 13:41
Sept 12 (Reuters) - Bright Minds Biosciences Inc
DRUG.CD :
* BRIGHT MINDS BIOSCIENCES INITIATES THE BREAKTHROUGH STUDY:
A
PHASE 2 TRIAL OF BMB-101 IN ABSENCE EPILEPSY AND DEVELOPMENTAL
EPILEPTIC ENCEPHALOPATHY
* BRIGHT MINDS BIOSCIENCES INC - FINANCIAL RUNWAY EXTENDING
INTO
2026
Source text for Eikon: ID:nPn95hM7ya
Further company coverage: DRUG.CD
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Bright Minds Biosciences
See all newsBright Minds Biosciences slips after increased $175 mln stock sale
Brief: Bright Minds Biosciences Announces Pricing Of Upsized US$175 Million Public Offering Of Common Stock At $90.00 Per Share
Bright Minds Biosciences falls after $100 mln equity offering launched
Brief: Bright Minds To Announce Topline Results For BMB-101 Phase 2 Trial In On Jan 6
Brief: Bright Minds Biosciences Files For Offering Of Up To 1.6 Million Common Shares By The Selling Securityholders